当前位置: X-MOL 学术Mol. Cell. Endocrinol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Heat shock proteins in thyroid malignancies: Potential therapeutic targets for poorly-differentiated and anaplastic tumours?
Molecular and Cellular Endocrinology ( IF 3.8 ) Pub Date : 2019-12-06 , DOI: 10.1016/j.mce.2019.110676
Giacomo Lettini 1 , Michele Pietrafesa 1 , Silvia Lepore 1 , Francesca Maddalena 1 , Fabiana Crispo 1 , Alessandro Sgambato 1 , Franca Esposito 2 , Matteo Landriscina 3
Affiliation  

Thyroid cancer is the most common endocrine malignancy, with well-differentiated subtypes characterized by an excellent prognosis due to their optimal sensitivity to standard therapies whereas poorly differentiated and anaplastic tumours by chemo/radio-resistance and unfavourable outcome. Heat Shock Proteins (HSPs) are molecular chaperones overexpressed in thyroid malignancies and involved in crucial functions responsible for thyroid carcinogenesis, as protection from apoptosis, drug resistance and cell migration. Thus, HSPs inhibitors have been proposed as novel therapeutic agents in thyroid cancer to revert molecular mechanisms of tumour progression. In this review, we report an overview on the biological role of HSPs, and specifically HSP90s, in thyroid cancer and their potential involvement as biomarkers. We discuss the rationale to evaluate HSPs inhibitors as innovative anticancer agents in specific subtypes of thyroid cancer characterized by poor response to therapies with the objective to target single family chaperones to reduce, simultaneously, the expression/stability of multiple client proteins.

中文翻译:

甲状腺恶性肿瘤中的热休克蛋白:低分化和间变性肿瘤的潜在治疗靶点?

甲状腺癌是最常见的内分泌恶性肿瘤,其高分化亚型的特征是预后良好,这是由于它们对标准疗法的最佳敏感性,而化学/放射耐药性导致的分化差和间变性肿瘤则具有不良的预后。热休克蛋白(HSP)是在甲状腺恶性肿瘤中过表达的分子伴侣,并参与负责甲状腺癌变的重要功能,以保护细胞免受凋亡,耐药性和细胞迁移。因此,已经提出了HSPs抑制剂作为甲状腺癌中的新型治疗剂以逆转肿瘤进展的分子机制。在这篇综述中,我们报告了HSPs,特别是HSP90s在甲状腺癌中的生物学作用及其作为生物标记物的潜在作用的概述。
更新日期:2019-12-06
down
wechat
bug